Home・Aandelen Lijst・ADMA Biologics Inc

ADMA Biologics Inc

Gesloten

SectorGezondheidszorg

8.26 -1.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.17

Max

8.39

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.1M 45M
Verkoop	-25M 114M
K/W Sectorgemiddelde	12.868 62.58
EPS	0.17
Winstmarge	39.59
Werknemers	640
EBITDA	-4.2M 61M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+123.06% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-367M 2B
Vorige openingsprijs	9.34
Vorige sluitingsprijs	8.26

Nieuwssentiment

By Acuity

91%

320 / 340 Rangschikking in Healthcare

ADMA Biologics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 jul 2026, 19:26 UTC

News

ADMA Biologics shares are lower amid a securities fraud lawsuit alleging inflated revenue growth and related party transactions, impacting investor sentiment.

22 jul 2026, 18:36 UTC

News

ADMA Biologics shares are lower as a class action lawsuit targets investors, alleging false statements about business practices and internal controls.

21 jul 2026, 19:36 UTC

News

ADMA Biologics Inc faces a class action lawsuit alleging securities fraud, contributing to its decline since Monday's close. Shares briefly rebounded earlier in the session.

20 jul 2026, 19:46 UTC

ADMA Biologics Inc shares are higher during Monday's session, despite fluctuations and no specific news to explain the price action since Friday's close.

Peer Vergelijking

Prijswijziging

ADMA Biologics Inc Prognose

Koersdoel

By TipRanks

123.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.67 USD 123.06%

Hoogste 21 USD

Laagste 17 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor ADMA Biologics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan ADMA Biologics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

320 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.